Gestational Age Cohort 1 Cohort 2 E VA (OD, OS) FU (y) EUAs E(OS)

Slides:

Advertisements

Similar presentations

Approach to pediatric retinal disease

Advertisements

Retina Conference Eddie Apenbrinck, M.D. University of Louisville

Retinoblastoma By Toni Dempsey Ben Landry Natalie Parsley Guy Staton Tiffany Wilcox Ashley Willmann.

R.I.C.H. Grand Rounds October 2005 Speaker: Jay C. Bradley, MD Discussant: Michael J. Shami, MD Rapidly Involuting Congenital Hemangioma.

Combined microsurgical and endoscopic removal of large brain lesions in children: a report of two cases Domagoj Jugović Andrej Porčnik Marjan Koršič University.

Outcome of 129 children after antenatal exposure to cancer treatment: Results of a case-control study from the International Network on Cancer, Infertility.

Central serous chorioretinopathy and uveitis Central serous chorioretinopathy and uveitis Rim Kahloun, MD Sonia Zaouali, MD Moncef Khairallah, MD Moncef.

Cryptococcus choroiditis

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Periocular Topotecan for Intraocular Retinoblastoma.

Pregnancy associated breast cancer (PABC)

Retinoblastoma Retinoblastoma is a rare form of eye cancer that develops in the retina usually before the age 5.

Image Guided Interstitial Brachytherapy For Locally Advanced Gynaecological Cancer With A MUPIT Applicator M.A.D. Haverkort, MD 1, E. Van der Steen - Banasik,

Cryptococcus neoformans Choroiditis Rupesh Agrawal, Ho Su Ling, Stephen Teoh Tan Tock Seng Hospital, National Healthcare Group Eye Institute, Singapore.

Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Inhibition of Neovascularization but Not Fibrosis.

The Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs Deferred Laser Treatment: 3-year.

Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.

The influence of pregnancy changes on myopic patients’ eyes

From: Outer Segment Thickness Predicts Visual Field Response to QLT in Patients with RPE65 or LRAT Mutations Trans. Vis. Sci. Tech ;4(5):8.

Macular Epiretinal membrane

Malignancies in patients less than 6 months at MAHAK hospital

The Diabetic Retinopathy Clinical Research Network

Retinoblastoma case - Brazil

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Copyright © 2013 American Medical Association. All rights reserved.

Volume 1, Issue 4, Pages (July 2017)

Copyright © 2007 American Medical Association. All rights reserved.

The Diabetic Retinopathy Clinical Research Network

Invest. Ophthalmol. Vis. Sci ;58(2): doi: /iovs Figure Legend:

Pars Plana Vitrectomy Combined with Internal Limiting Membrane Peeling to Treat Persistent Macular Edema after Anti-Vascular Endothelial Growth Factor.

Intravitreal Methotrexate for Retinoblastoma

Glaucoma Progression.

Sarosh A. Janjua MD1, Sandra L. Cremers MD FACS1

What does this protein make up or do?

Anterior Uveitis in a Child

RETINOBLASTOMA By: Kristin Gartman Kristen Ryan Mario Cotton.

Figure 2 Evolution of MRI abnormalities in faciobrachial dystonic seizures Axial fluid- attenuated inversion recovery (FLAIR)-weighted images from patient.

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

January 16, 2019.

Multiple evanescent white dot syndrome

Volume 379, Issue 9824, Pages (April 2012)

Sarah H. Van Tassel, MD, Sanjay G. Asrani, MD Ophthalmology Glaucoma

Clinical responses in patients.

خدا نام به.

Volume 21, Issue 3, Pages e4 (September 2017)

Studied for effect of delayed enucleation on mortality

A–E, Active avoidance (A–D) and optokinetic testing (E) in an independent cohort. A–E, Active avoidance (A–D) and optokinetic testing (E) in an independent.

خدا نام به.

Volume 18, Issue 10, Pages (October 2010)

A B C D E Biopsy (incisional) Biopsy (excisional)

Pre-Laser Fundus images Post-Laser Fundus images

A B C Figure 1(A-C): A. RetCam at time of presentation (Images by Leslie MacKeen) showing a macular tumor (IIRC group B). B- B-scan Ultrasound at time.

The impact of chronic endometritis on reproductive outcome

Pseudoresponse. Pseudoresponse. A 47-year-old man with GBM. A reduction of the enhancing portion of the lesion is observed 1 day after initiation of cediranib.

A I II 1 2 H1 H0 20/ logMAR B F+F C D Figure 1. (A) Pedigree of a family with a unilaterally affected father discovered to be mosaic (H1) for a high.

Studied for effect of delayed enucleation on mortality

Figure 3: Female patient, 57 years old

A B C Figure 1(A-C): A. RetCam at time of presentation (Images by Leslie MacKeen) showing a macular tumor (IIRC group B). B- B-scan Ultrasound at time.

Can cervical length monitoring and treatment affect prematurity rate?

* * ↨ ↨ * * ↨ ↨ Figure 1: Early awareness of risk for retinoblastoma optimizes therapy and outcomes. This child was examined because his sibling (triplets)

Studied for effect of delayed enucleation on mortality

Gestational Age Cohort 1 Cohort 2 E E(OS) E(OD) FU (y) IIRC (OD, OS)

Multiple Evanescent White Dot Syndrome (MEWDS)

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

Kaplan–Meier plots of survival by gestational week for babies born at 23–26 weeks of gestation in level 3 and level 2 centres in England in Kaplan–Meier.

Figure 1: Inclusion and Exclusions

Figure 1: Inclusion and Exclusions

B1 b2 a Figure 1: Inclusion and Exclusions. Included eyes had (a) juxtafoveal tumor (yellow box) encroaching on the fovea with preserved foveal pit (yellow.

Presentation transcript:

Gestational Age Cohort 1 Cohort 2 E VA (OD, OS) FU (y) EUAs E(OS) IIRC (OD, OS) EUAs 1 A, A 25 20/20; 20/20 5.6 2 C, B 43 20/200* 3.7 E(OS) 3 A, B 20/20; E 18 41 E(OS) 4 20/20, E A, B 24 7.1 Cohort 1 5 A, B 20/20; 20/200 18 (OS) 22 E(OD) 6 B, A 30 NPL; 20/25 2.7 7 A, B 20/30; 20/30 2.8 23 8 E(OD) D, A 18 E; 20/20 2.4 Figure 1. Tumor timing, therapy and outcomes. Patients in each of the postnatal and prenatal retinoblasotma detection shown by gestational age at birth, international intraocular retinoblastoma classification (IIRC), treatment at time of first tumor occurrence and subsequently, final visual outcome and total follow-up time. E(OD) 9 (OU) B, B 81 E; 20/400 15.5 10 A, A 41 20/30; 20/60 15.5 11 B, A 21 20/20; 20/25 14.8 12 B, B 33 20/600; 20/60 5.2 E(OD) 13 (OU) B, B 28 E; 20/30 4.9 14 A, A 20/15; 20/10 12.8 36 15 A, A 30 20/50; 20/20 9.5 Cohort 2 A, A 16 30 20/20; 20/25 8.8 17 A, A 22 20/20; 20/25 3.8 A, A 4.3 18 24 20/20; 20/25 19 B, B 31 20/25; 20/100 6.4 20 B, B 20 20/125; 20/25 3.2 21 A, A 21 20/25; 20/25 2.3 28 29 30 31 32 33 34 35 36 37 38 39 40 1 2 3 4 5 6 7 8 9 10 E Focal Therapy Chemotherapy Radiotherapy Enucleation weeks months Spontaneous birth Induced birth Birth to first tumor Gestational Age

A B Figure 2. Prenatal Detection of Retinoblastoma (Case 18). At birth (28 weeks gestation; spontaneously premature), no tumors were observed (not shown). The first tumor appeared in the left eye on imaging with OCT (A,B) and RetCam (C) at 3 years of age and was treated with focal therapy alone (D). C D

OD OS A B Figure 3. Postnatal detection of retinoblastoma (Case 2). At birth (39 weeks gestation), large macular tumours were observed in each eye (A,B, patient 5 days old). Too young for systemic chemotherapy, the child was treated first with focal therapy including laser and periorbital topotecan. Systemic chemotherapy was later required to control tumor growth (C,D, patient 3.5 years old). C D

Gestational Age Term delivery Preterm delivery E VA (OD, OS) FU (y) IIRC (OD, OS) EUAs 1 A, A 25 20/20; 20/20 5.6 2 C, B 42 20/200* 3.7 E(OS) 3 A, B 20/20; E 18 Term delivery 41 E(OS) 4 20/20, E A, B 24 7.1 5 A,B (OS) 22 20/20; 20/200 18 6 B,A 26 NPL; TBD 2.7 7 A,A TBD; TBD 2.8 22 8 E(OD) D,A 17 E; 20/20 2.4 Figure 1. Tumor timing, therapy and outcomes. Patients in each of the postnatal and prenatal retinoblasotma detection shown by gestational age at birth, international intraocular retinoblastoma classification (IIRC), treatment at time of first tumor occurrence and subsequently, final visual outcome and total follow-up time. E(OD) 9 (OU) B,B 81 E; 20/400 15.5 10 A, A 41 20/30; 20/60 15.5 11 B,A 21 20/20; 20/25 14.8 12 B,B 33 20/600; 20/60 5.2 E(OD) 13 (OU) B,B 28 E; 20/30 4.9 14 A,A 20/15; 20/10 12.8 36 15 A,A 30 20/50; 20/20 9.5 Preterm delivery A,A 16 30 20/20; 20/25 8.8 17 20/20; 20/25 3.8 A,A 22 A,A 4.3 18 24 20/20; 20/25 19 B,B 31 20/25; 20/100 6.4 20 B,B 19 20/125; 20/25 3.2 21 A,A 19 TBD; TBD 2.3 28 29 30 31 32 33 34 35 36 37 38 39 40 1 2 3 4 5 6 7 8 9 10 weeks months E Focal Therapy Chemotherapy Radiotherapy Enucleation Spontaneous birth Induced birth Birth to first tumor Gestational Age